Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03368339 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
A Phase 2 study of Allergic Conjunctivitis, sponsored by Realm Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT03368339 is a Phase 2 study of Allergic Conjunctivitis that has completed, run by Realm Therapeutics. The registered enrollment target is 96 participants, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03368339, a Phase 2 study of Allergic Conjunctivitis, has completed, sponsored by Realm Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis using a modified Conjunctival Allergen Challenge Model (Ora-CAC®).
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG PR013 (0.045%)
- DRUG PR013 (0.06%)
Study Locations (1)
Pennsylvania
- Principal Investigator - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2017-12-10 |
| Est. Completion | 2018-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03368339
The ClinicalTrials.gov registry entry for NCT03368339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (26% lower). The listed sponsor is Realm Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT03368339 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03368339 about?
NCT03368339 is a clinical study titled "Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis". To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis using a modified Conjunctival Allergen Challenge Model (Ora-CAC®).
What is the current status of trial NCT03368339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2017-12-10. Estimated completion is 2018-01-28.
What conditions does trial NCT03368339 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT03368339?
The interventions under investigation include: Vehicle (DRUG), PR013 (0.045%) (DRUG), PR013 (0.06%) (DRUG).
Who is sponsoring clinical trial NCT03368339?
This trial is sponsored by Realm Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03368339 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
COMPLETED · Phase 2
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.